Ortoma (ORT) Q4 2024 earnings summary

Executive summary

• Revenue for 2024 increased to SEK 49.1 million from SEK 38.1 million year-over-year, driven by product sales and milestone payments.

• EBITDA for the full year turned positive at SEK 5.1 million, compared to SEK -15.8 million in 2023.

• Net result after financial items improved to SEK -5.9 million from SEK -21.9 million year-over-year.

• Commercialization phase initiated, with first deliveries of OTS® Hip Systems to the US and positive clinical feedback from Japan.

• Leadership transition: Fredrik Strömberg appointed as new CEO effective May 15, 2025.

Financial highlights

• Q4 2024 revenue was SEK 17.3 million, up from SEK 15.6 million in Q4 2023.

• Q4 EBITDA improved to SEK -2.3 million from SEK -15.8 million year-over-year.

• Full-year net result per share was SEK -0.16, compared to SEK -1.10 in 2023.

• Cash and cash equivalents at year-end were SEK 17.8 million, down from SEK 51.4 million.

• No dividend proposed for 2024.

Outlook and guidance

• US and European launches planned upon regulatory approvals, with initial installations at leading US surgeons.

• Recurring revenue share expected to grow as installed base increases and more systems are in clinical use.

• 2025 anticipated to be a year of intensified commercialization and product launches.